BOSTON, February 2, 2022 — COTA, Inc., an oncology real-world data (RWD) and analytics company, announced today that Paige Whitney will join the executive leadership team as Senior Vice President of Life Sciences. Paige is responsible for growing the company’s industry partnerships and strengthening COTA’s position as a leading provider of oncology RWD.
Paige brings more than 20 years of business development experience, all of which has been in the healthcare industry. Prior to COTA, Paige spent five years at Aetion, a real-world evidence company, where she was instrumental in accelerating growth. As a result, she is well-versed in both the value and complexities of RWD and evidence generation. Before Aetion, Paige spent more than a decade at Premier where she drove RWD adoption to improve patient care.
COTA has made diversity and inclusion a priority with a focus on building a team of executive leaders with diverse backgrounds, expertise, and points of view. With Paige’s promotion, the company’s leadership team is predominantly female with seven out of ten members identifying as a person of color.
“Building a team that lives and breathes our mission to bring clarity to cancer care is priority one. Paige has proven her steadfast commitment to achieving this mission since joining COTA just last year. Equally important to our shared success is the team’s ability to bring unique backgrounds, cultures, perspectives, and opinions to the table – and to push each other to critically think about the decisions we are making as a business and the impact they will have on patients, providers, and the life sciences community.”
Paige’s immediate priority is to expand her team to meet the growing demand for COTA’s RWD across the pharma ecosystem. Additionally Paige will play a leadership role in developing the go-to-market strategy for the company’s new data offerings, advanced analytics, and evidence generation capabilities.
"Cancer is a disease that impacts every single person across the globe. Being able to spend my time focused on helping life sciences companies fast-track their oncology drug approvals and pipelines for the benefit of cancer patients is meaningful work. I am honored to have the expanded responsibilities that come with my new role, and I am more committed than ever to ensuring we do our part at COTA to make precision oncology a reality."
